Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4336144 | 0.88 | LMNA (0.34) | LMNAMEN1KMT2AHTR7ADORA3 | |
| SCHEMBL19940946 | 0.86 | KDM1A (0.37) | LMNAMEN1KMT2AHTR7ADORA3 | |
| SCHEMBL18109699 | 0.84 | SLC10A2 (0.38) | LMNAMEN1KMT2A | |
| SCHEMBL485258 | 0.83 | LMNA (0.38) | LMNAMEN1KMT2AHTR7ADORA3 | |
| SCHEMBL18109314 | 0.82 | MMP2 (0.37) | LMNAMEN1KMT2A | |
| SCHEMBL19991844 | 0.81 | MMP2 (0.39) | LMNAMEN1KMT2A | |
| SCHEMBL4339935 | 0.81 | TDP1 (0.35) | LMNAMEN1KMT2AHTR7ADORA3 | |
| SCHEMBL5804792 | 0.81 | TDP1 (0.35) | LMNAMEN1KMT2AHTR7ADORA3 | |
| SCHEMBL5807914 | 0.80 | CYP19A1 (0.33) | LMNAHTR7CA2 | |
| SCHEMBL4330497 | 0.80 | CYP19A1 (0.33) | LMNAHTR7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612226-B2 | Amino acid derivatives | PFIZER INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612226-B2 | Amino acid derivatives | PFIZER INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1879567-A1 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060247291-A1 | Amino acid derivatives | PFIZER, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006114707-A1 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006092692-A1 | USE OF COMBINATIONS OF PDE7 INHIBITORS AND ALPHA-2-DELTY LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247291-A1 | Amino acid derivatives | OPRL1, BCAT2, BCAT1 | LMNA 4367/4885MEN1 3595/4885KMT2A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.